CARISMA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.48 USD | -1.99% |
|
-8.64% | -49.49% |
| 05-09 | Carisma Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 05-02 | Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer | CI |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 118.2 | 61.48 | - | - |
| Enterprise Value (EV) 1 | 118.2 | 61.48 | 61.48 | 61.48 |
| P/E ratio | -1.13 x | -1.33 x | -1.29 x | -2.04 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | 7.93 x | 3.83 x | 3.8 x | 1.81 x |
| EV / Revenue | 7.93 x | 3.83 x | 3.8 x | 1.81 x |
| EV / EBITDA | - | - | - | - |
| EV / FCF | -1.44 x | -1.76 x | -1.13 x | -1.56 x |
| FCF Yield | -69.6% | -56.9% | -88.6% | -64.2% |
| Price to Book | - | - | - | - |
| Nbr of stocks (in thousands) | 40,357 | 41,543 | - | - |
| Reference price 2 | 2.930 | 1.480 | 1.480 | 1.480 |
| Announcement Date | 01/04/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 14.92 | 16.07 | 16.2 | 34 |
| EBITDA | - | - | - | - | - |
| EBIT 1 | - | -88.73 | -55.04 | -67.91 | -63.23 |
| Operating Margin | - | -594.75% | -342.51% | -419.26% | -185.97% |
| Earnings before Tax (EBT) 1 | - | -86.88 | -48.45 | -60.82 | -31.4 |
| Net income 1 | -61.23 | -86.88 | -59.43 | -63.72 | -53.84 |
| Net margin | - | -582.34% | -369.79% | -393.43% | -158.36% |
| EPS 2 | -54.65 | -2.590 | -1.113 | -1.150 | -0.7250 |
| Free Cash Flow 1 | - | -82.31 | -35 | -54.5 | -39.5 |
| FCF margin | - | -551.71% | -217.78% | -336.48% | -116.18% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 04/04/23 | 01/04/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 3.243 | 3.56 | 3.827 | 4.289 | 3.397 | 3.598 | 3.598 | 3.548 | 2.399 | 2.399 |
| EBITDA | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -22.97 | -20.96 | -22.34 | -22.45 | -19.51 | -12.79 | -11.33 | -11.41 | -11.87 | -12.98 |
| Operating Margin | -708.36% | -588.9% | -583.85% | -523.43% | -574.33% | -355.44% | -314.95% | -321.56% | -494.94% | -541% |
| Earnings before Tax (EBT) 1 | -24.53 | -19.79 | -21.4 | -21.16 | -18.98 | -12.1 | -8.835 | -8.539 | -9.265 | -10.92 |
| Net income 1 | -24.64 | -19.88 | -21.4 | -20.96 | -18.98 | -12.1 | -8.835 | -8.539 | -9.265 | -10.92 |
| Net margin | -759.85% | -558.31% | -559.26% | -488.65% | -558.67% | -336.22% | -245.52% | -240.64% | -386.2% | -455.4% |
| EPS 2 | -1.930 | -0.4900 | -0.5300 | -0.4800 | -0.4600 | -0.2933 | -0.2267 | -0.2067 | -0.2300 | -0.2600 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/05/23 | 10/08/23 | 09/11/23 | 01/04/24 | 09/05/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | -82.3 | -35 | -54.5 | -39.5 |
| ROE (net income / shareholders' equity) | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex 1 | - | - | - | 1 | 2 |
| Capex / Sales | - | - | - | 6.17% | 5.88% |
| Announcement Date | 04/04/23 | 01/04/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.48
USD
Average target price
8.4
USD
Spread / Average Target
+467.57%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -49.49% | 61.48M | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- CARM Stock
- Financials Carisma Therapeutics, Inc.
